DelveInsight’s, “Plaque Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Plaque Psoriasis Pipeline Report

• DelveInsight’s Plaque Psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Plaque Psoriasis treatment.
• The leading companies working in the Plaque Psoriasis Market include Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others.
• Promising Plaque Psoriasis Pipeline Therapies in the various stages of development include Tapinarof, Tapinarof cream 1%, Bimekizumab, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), and others.
• September 2023: Dermavant Sciences Inc. announced a study of phase 3 clinical trials for Tapinarof Cream 1%. This study is an open-label study, consisting of a 12-week primary treatment phase and an optional 40-week long-term extension phase in which all eligible subjects will receive tapinarof cream, 1% once daily. At the end of the 12-week primary treatment phase subjects will have the option to continue for 40 additional weeks of treatment.
• September 2023: Hangzhou Highlightll Pharmaceutical Co., Ltd announced a study of phase 2 clinical trials for TLL018 tablets. This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.

 

Request a sample and discover the recent advances in Plaque Psoriasis Treatment Drugs @ Plaque Psoriasis Pipeline Report

 

In the Plaque Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Plaque Psoriasis Overview

Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and associated with abnormalities of other systems. Plaque psoriasis is the commonest clinical type of psoriasis. Even though the condition is not life-threatening, it is difficult to treat and response rates vary widely.

 

Find out more about Plaque Psoriasis Therapeutics Assessment @ Plaque Psoriasis Preclinical and Discovery Stage Products

 

Plaque Psoriasis Emerging Drugs Profile

• ARQ-151: Arcutis Biotherapeutics
• ABY-035: Affibody
• AK101: Akeso Biopharma

 

Plaque Psoriasis Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Plaque Psoriasis therapies. The Plaque Psoriasis companies which have their Plaque Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, Arcutis Biotherapeutics.

 

Learn more about the emerging Plaque Psoriasis Pipeline Therapies @ Plaque Psoriasis Clinical Trials Assessment

 

Scope of the Plaque Psoriasis Pipeline Report

• Coverage- Global
• Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Plaque Psoriasis Companies- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others.
• Plaque Psoriasis Pipeline Therapies- Tapinarof, Tapinarof cream 1%, Bimekizumab, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), and others.

 

Dive deep into rich insights for new drugs for Plaque Psoriasis treatment, Visit @ Plaque Psoriasis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Plaque Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Plaque Psoriasis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. ARQ-151: Arcutis Biotherapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABY-035: Affibody
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CT303: GC Cell
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Plaque Psoriasis Key Companies
21. Plaque Psoriasis Key Products
22. Plaque Psoriasis- Unmet Needs
23. Plaque Psoriasis- Market Drivers and Barriers
24. Plaque Psoriasis- Future Perspectives and Conclusion
25. Plaque Psoriasis Analyst Views
26. Plaque Psoriasis Key Companies
27. Appendix

 

For further information on the Plaque Psoriasis pipeline therapeutics, reach out to Plaque Psoriasis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking